Skip to main content
Equibles
KYMR logo

KYMR · Kymera Therapeutics, Inc.

Track KYMR — free

Use KYMR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYMR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$127.57 +0.40 (+0.31%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$10.89B
Shares
85.37M
Volume · Nov 13 808.83K Avg daily vol (3M) 828.66K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$127.57 Open$126.93 Day$124.90–129.78 52W close$63.63–138.86 Avg vol 30d957K Short int8.4M · 9.8% of shares · 10.5d Short vol67% Last earningsOct 29, 2026 DataAug 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Next earnings call
Feb 25, 2027 Est · unconfirmed · in 15 wks
Q2 2026 earnings call transcript
call held Aug 5, 2026
Play latest call

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
R&D spending rises as quarterly loss widens

Kymera Therapeutics posted a $132.0 million net loss for the quarter ended September 30, 2026 as research and development expenses rose to $128.5 million from $74.1 million. Cash, cash equivalents and marketable securities were $1,646 million, expected to fund operations into 2029.

Revenue $0 Net loss $132M Diluted EPS -$1.32
Read from the MD&A section
3 source passages
We reported net losses of $132.0 million and $262.4 million for the three and nine months ended September 30, 2026 respectively, and $82.2 million and $224.4 million for the three and nine months ended September 30, 2025, respectively. Research and development expenses were $128.5 million for the three months ended September 30, 2026, compared to $74.1 million for the three months ended September 30, 2025. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $1,646 million. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029, beyond multiple clinical inflection points in our pipeline. Open the document at this passage
Oct 29
Current report 8-K
Financial results

Kymera Therapeutics reported third-quarter 2026 results: a $132.0 million net loss and $1.6 billion in cash, cash equivalents and investments as of September 30, 2026. KT-579 Phase 1 results were positive, while KT-621 BROADEN2 topline data are planned by year-end 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$102.24M
Trailing 12 months
Net income (TTM)
−$349.43M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-396.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$371.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.7%
Year over year · more shares
Price change (1Y)
+100.5%
Trailing year
Short interest
9.8%
Latest settlement · 10.5 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼84.6% $7.39M −$70.75M '24 Q4* ▲114.8% $22.10M −$65.58M '25 Q1 ▼55.3% $11.48M −$76.61M '25 Q2 ▼26.1% $2.76M −$82.17M '25 Q3 ▼61.2% $2.87M −$86.98M '25 Q4* ▲55.5% $34.37M −$69.23M '26 Q1 ▲466.4% $65.00M −$61.21M '26 Q2 LATEST ▼100% $0 −$132.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Kymera completed enrollment in the KT-621 BROADEN2 Phase 2b AD trial about six months ahead of schedule, pulling forward topline data to year-end 2026 and planned Phase 3 initiation to mid-2027, while reporting $65M in Q2 collaboration revenue and reaffirming a cash runway into 2029.

Bullish
  • + KT-621 BROADEN2 Phase 2b AD enrollment completed ~6 months early, pulling data readout forward to year-end 2026 and Phase 3 start to mid-2027
  • + KT-579 (IRF5) Phase 1 healthy volunteer data expected 4Q26, with Phase 1b lupus POC study planned shortly after
  • + Sanofi-initiated KT-485 Phase 1 triggered $20M milestone; Gilead exercised KT-200 option for $45M
  • + Robust $1.5B cash position with runway into 2029, supporting Phase 2 completions and start of Phase 3 programs
Bearish
  • − R&D expenses rose sharply year-over-year to $119.5M in Q2 2026
  • − No additional collaboration revenue expected in 2026 after $65M already recognized, pressuring remaining-year revenue

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +28%
above
Price vs 50-day avg +9%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 85%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +22%
trailing
6-month return +58%
trailing
YTD return +64%
this year
Relative strength +57%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $117 › 200d $99 — 50d above 200d
Institutional flow Accumulating
229 of 286 funds reported for Sep 30 · net +1.3M sh shares · +35 new
Insider flow Distributing
Net -$744.3K over 90 days · 100% sells
Short interest Falling
9.84% of shares out · ▼ -8.4% MoM · 10.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
286 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth −17%
Y/Y
EPS growth −24%
Y/Y
Free cash flow $-234.3M
Balance sheet $353.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −28%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+28% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
85% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $117 › 200d $99 — 50d above 200d
Institutional flow Accumulating
229 of 286 funds reported for Sep 30 · net +1.3M sh shares · +35 new
Insider flow Distributing
Net -$744.3K over 90 days · 100% sells
Short interest Falling
9.84% of shares out · ▼ -8.4% MoM · 10.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
286 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $64 Now $128 · 85% Range high $139
vs 200-day avg +28% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KYMR
Kymera Therapeutics, Inc.
this stock
$10.89B +64.0% -16.7% — 9.8%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
312
% held
116.1%
Reported
229 of 286
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
389
View
Short & Settlement
Short Interest Falling
Shares short
8.4M
Days to cover
10.5d
Change
-770.6K sh
View
Short Volume
Short vol %
67%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$107
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
48.4%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$744.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$39.2M
Net income (FY)
$-311.4M
EPS diluted
$-3.69
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
24

Kymera Therapeutics posted a $132.0 million net loss for the quarter ended September 30, 2026 as research and development expenses rose to $128.5 million from $74.1 million. Cash, cash equivalents and marketable securities were $1,646 million, expected to fund operations into 2029.

View
Proposed Sales
Value
$3.4M
Shares
30.0K
Filed
Oct 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Kymera Therapeutics Announces Thi…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
KYMR -3.2% +21.8% +57.9% +0.7% +64.0%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.8% +22.9% +57.4% +0.9% +53.3%
Key facts CIK 1815442 CUSIP 501575104 13F (30d) 236 filings 211 filers Visit website Investor relations